Roche Drug Is First To Extend Survival Significantly
- Posted on: Nov 24 2015
Until now, no treatment has increased survival significantly in melanoma patients with metastases – cancer cells that have spread beyond the original tumor site. Average survival for Stage III and IV patients has been about eight months. However, a Phase III controlled trial of the experimental drug RG7204 (aka PLX4032), manufactured by the Swiss drug giant Roche, has just concluded, with patients on the drug living significantly longer than those on dacarbazine, the only FDA-approved chemotherapy for melanoma.
Posted in: What's New